These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 31126017)

  • 1. Biological Rationale for Targeting MEK/ERK Pathways in Anti-Cancer Therapy and to Potentiate Tumour Responses to Radiation.
    Marampon F; Ciccarelli C; Zani BM
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting ERK1/2 protein-serine/threonine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Apr; 142():151-168. PubMed ID: 30794926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extracellular-Regulated Kinases: Signaling From Ras to ERK Substrates to Control Biological Outcomes.
    Eblen ST
    Adv Cancer Res; 2018; 138():99-142. PubMed ID: 29551131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained activation of the extracellular signal-regulated kinase pathway protects cells from photofrin-mediated photodynamic therapy.
    Tong Z; Singh G; Rainbow AJ
    Cancer Res; 2002 Oct; 62(19):5528-35. PubMed ID: 12359764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitogen-activated protein kinases and Hedgehog-GLI signaling in cancer: A crosstalk providing therapeutic opportunities?
    Rovida E; Stecca B
    Semin Cancer Biol; 2015 Dec; 35():154-67. PubMed ID: 26292171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
    Roberts PJ; Der CJ
    Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.
    Friday BB; Adjei AA
    Clin Cancer Res; 2008 Jan; 14(2):342-6. PubMed ID: 18223206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERK/MAPK signalling pathway and tumorigenesis.
    Guo YJ; Pan WW; Liu SB; Shen ZF; Xu Y; Hu LL
    Exp Ther Med; 2020 Mar; 19(3):1997-2007. PubMed ID: 32104259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-alpha2b reduces phosphorylation and activity of MEK and ERK through a Ras/Raf-independent mechanism.
    Romerio F; Riva A; Zella D
    Br J Cancer; 2000 Aug; 83(4):532-8. PubMed ID: 10945503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants.
    Brognard J; Dennis PA
    Cell Death Differ; 2002 Sep; 9(9):893-904. PubMed ID: 12181740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression and significance of MAPK/ERK in the specimens and cells of epithelial ovarian cancer].
    Jiang XL; Gao JC; Jiang L; Zhang PX; Kang TJ; Sun Q; Qi WJ; Zhang QP; Guan HW; Shi H
    Zhonghua Fu Chan Ke Za Zhi; 2019 Aug; 54(8):541-547. PubMed ID: 31461811
    [No Abstract]   [Full Text] [Related]  

  • 13. Recent developments in mitogen activated protein kinase inhibitors as potential anticancer agents.
    Singh VJ; Sharma B; Chawla PA
    Bioorg Chem; 2021 Sep; 114():105161. PubMed ID: 34328852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p38 mitogen-activated protein kinase-dependent activation of protein phosphatases 1 and 2A inhibits MEK1 and MEK2 activity and collagenase 1 (MMP-1) gene expression.
    Westermarck J; Li SP; Kallunki T; Han J; Kähäri VM
    Mol Cell Biol; 2001 Apr; 21(7):2373-83. PubMed ID: 11259586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sphingosine-1-phosphate stimulates human Caco-2 intestinal epithelial proliferation via p38 activation and activates ERK by an independent mechanism.
    Thamilselvan V; Li W; Sumpio BE; Basson MD
    In Vitro Cell Dev Biol Anim; 2002 Apr; 38(4):246-53. PubMed ID: 12197778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
    Wang AX; Qi XY
    IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway.
    Kidger AM; Sipthorp J; Cook SJ
    Pharmacol Ther; 2018 Jul; 187():45-60. PubMed ID: 29454854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-related reductions in the activation of mitogen-activated protein kinases p44mapk/ERK1 and p42mapk/ERK2 in human T cells stimulated via ligation of the T cell receptor complex.
    Whisler RL; Newhouse YG; Bagenstose SE
    Cell Immunol; 1996 Mar; 168(2):201-10. PubMed ID: 8640866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Extracellular Signal-Regulated Protein Kinase 1/2 (ERK1/2) in Cancer: An Update on Pharmacological Small-Molecule Inhibitors.
    Fu L; Chen S; He G; Chen Y; Liu B
    J Med Chem; 2022 Oct; 65(20):13561-13573. PubMed ID: 36205714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy.
    Yu Z; Ye S; Hu G; Lv M; Tu Z; Zhou K; Li Q
    Future Med Chem; 2015; 7(3):269-89. PubMed ID: 25826360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.